An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Avelumab (MSB0010718C) Clinical Studies - Avelumab Program Rollover Study

Merck KGaA0 个研究点目标入组 312 人开始时间: 2019年2月19日最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•- Participants under enrollment and treatment in an avelumab clinical study under the sponsorship of Merck KGaA
•- Participants currently enrolled in an avelumab parent study and are on active treatment with avelumab or in long-term survival follow-up after treatment
•- Participants on active treatment must agree to continue to use highly effective contraception (that is, methods with a failure rate of less than 1% per year) for both male and female participants if the risk of conception exists
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 103
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 209

•- Participants who are pregnant or breastfeeding
•- Participants still on active treatment: Known hypersensitivity to any of the study intervention ingredients
•- Participant has been enrolled in the comparator arm of avelumab parent study
•- Participant has been withdrawn from avelumab parent study for any reason
•- Any other reason that, in the opinion of the Investigator, precludes the participant from participating in the study

发起方